Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV
Chun‐Jen Liu(National Taiwan University), Pei‐Jer Chen(National Taiwan University Hospital), Wan‐Long Chuang(Kaohsiung Medical University), Grégory Camus(Gilead Sciences (United States)), Benedetta Massetto(Gilead Sciences (United States)), Steven Knox(Gilead Sciences (United States)), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Deyuan Jiang(Gilead Sciences (United States)), Chi-Yi Chen(Chia-Yi Christian Hospital), John G. McHutchison(Gilead Sciences (United States)), Cheng‐Yuan Peng(China Medical University), Jyh-Jou Chen(Chi Mei Medical Center), Horng‐Yuan Wang(Mackay Memorial Hospital), Jenny C. Yang(Gilead Sciences (United States)), Gin‐Ho Lo(E-Da Hospital), Chi‐Jen Chu(Taipei Veterans General Hospital), Diana M. Brainard(Gilead Sciences (United States)), You-Chun Hsu(Changhua Christian Hospital), Ting‐Tsung Chang(National Cheng Kung University Hospital), I‐Shyan Sheen(Chang Gung Memorial Hospital), Chohee Yun(Gilead Sciences (United States)), Ron‐Nan Chien(Keelung Chang Gung Memorial Hospital), Anu Osinusi(Gilead Sciences (United States))
Cited by 118
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k